Nykode Therapeutics Expands its Clinical Collaboration and Supply Agreement with Roche to Evaluate VB10.16 for Advanced Cervical Cancer
Shots:
- The companies expanded their collaboration to evaluate Nykode’s VB10.16, a wholly owned off-the-shelf therapeutic cancer vaccine candidate in the (VB-C-04) trial for patients with advanced cervical cancer in combination with Roche’s atezolizumab. The trial is expected to be initiated in the US in Q4’23 & will be conducted with GOG Foundation
- Nykode will be responsible to sponsor & fund the planned clinical trial and hold all commercial rights to VB10.16 globally. Roche will provide atezolizumab
- The P-II study (VB-C-02) results for advanced cervical cancer showed ORR (29%) in patients treated with VB10.16 + atezolizumab, m-OS (not reached) but ≥25mos. at the time of analysis, and m-PFS (6.3mos.) in PD-L1+ patients
Ref: Nykode | Image: Nykode
Related News:- Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
